Abstract: The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.

Abstract: The present invention discloses a method for increasing the pool of Ngn3+ endocrine progenitor cells obtained from stem cells, by contacting said stem cells with a SUR1/Kir6.2 channel inhibitor. The invention also relates to a method for increasing the mass of pancreatic endocrine cells, in particular of ? cells. The invention further concerns a method for treating diabetes.

Abstract: The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.

Abstract: The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders.

Abstract: The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and/or prevention of eye diseases associated with ischemia and/or retinal excitotoxicity.

Abstract: The present invention discloses a method for increasing the pool of Ngn3+ endocrine progenitor cells obtained from stem cells, by contacting said stem cells with a SUR1/Kir6.2 channel inhibitor. The invention also relates to a method for increasing the mass of pancreatic endocrine cells, in particular of ? cells. The invention further concerns a method for treating diabetes.

Abstract: The present invention concerns a method for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) for an individual, wherein said method comprises determining the length of the polyalanine repeat of the protein encoded by at least one allele of the FOXE1 (Forkhead box E1) gene in a tissue sample obtained from said individual; and a kit for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) in an individual comprising at least one nucleic acid probe or oligonucleotide which can be used in such a method.

Abstract: The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders.

Abstract: The disclosure relates to the stimulation of an endocrine cell, in particular a pancreatic cell or its precursor, to grow and divide upon exposure to a neurotrophic agent such as nerve growth factor, laminin or both.